Deep Tech · Corporate VC

IBM Ventures

Strategic CVC arm of IBM treating quantum as co-equal with AI under Emily Fontaine; backs the software layer around IBM's hardware (Qedma, QunaSys, Strangeworks, SQK, QodeX Quantum, plus a 2022 Quantinuum position now listed on Nasdaq) and plugs portfolio companies into the IBM Quantum platform and Qiskit ecosystem.

Active Armonk, United StatesFounded 2024

Investment thesis

IBM Ventures is IBM's corporate venture arm, anchored by a $500M Enterprise AI Venture Fund announced in November 2023 with IBM as sole investor. Under Emily Fontaine, VP and Global Head of Venture Capital since mid-2024, quantum has been elevated to a co-priority with AI: 6 of the 28 active portfolio companies are quantum, and IBM's parent committed over $10B to quantum computing in June 2026.

The quantum strategy deliberately targets the software and algorithm layers that make IBM's own hardware more useful, never competing stacks: Qedma (error suppression and mitigation, $26M Series A led by Glilot with IBM participating, Jul 2025), QunaSys (quantum chemistry, direct investment 2023), Strangeworks (developer platform, Series A 2023), and two Feb 2026 seeds from the Duality/Alchemist Chicago accelerator, SQK (quantum-AI medical imaging) and QodeX Quantum (quantum-native AI).

One full-stack exception proves the ecosystem logic: IBM invested in Quantinuum in February 2022 (after backing Cambridge Quantum early), a position that went public when Quantinuum listed on Nasdaq (QNT) in June 2026.

Value-add is the capital-plus model: access to the IBM Quantum platform (600K+ registered users as of 2024, 340+ Quantum Network members), Qiskit, IBM Consulting client introductions, and a published roadmap to Starling, the large-scale fault-tolerant system targeted for 2029. IBM claims 90% portfolio engagement.

Anti-thesis

The patterns that trigger a fast no with this fund.

  1. Hardware conflict: companies competing with IBM's superconducting modular roadmap (or full-stack rivals beyond the legacy Quantinuum position) are structurally off-thesis
  2. Partnership is not capital: most IBM Quantum Network and Qiskit relationships never convert into equity (Algorithmiq runs on IBM hardware and sells on Qiskit Functions without IBM on its cap table); do not read ecosystem proximity as investment intent
  3. Qiskit agenda: every check serves IBM's platform lock-in; founders building hardware-agnostic or rival-stack-first products will face pressure to prioritize the IBM roadmap
  4. Pace and role: a handful of quantum checks since 2022, always as a follower with undisclosed amounts; this is strategic signal money, not a round-maker, and it cannot anchor your raise

Notable quantum portfolio

Full portfolio
QedmaQuantinuumQunaSysStrangeworksSQKQodeX Quantum

Frequent co-investors

  • Glilot Capital Partners
  • Korean Investment Partners
  • TPY Capital
  • Hitachi Ventures
  • Raytheon Technologies
  • Lightspeed Venture Partners
  • JPMorgan Chase
  • Mitsui
  • Honeywell